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Abstract
Proton relative biological effectiveness (RBE) is known to depend on the (α/β)x
of irradiated tissues, with evidence of ∼60% variation over (α/β)x values
from 1–10 Gy. The range of (α/β)x values reported for prostate tumors (1.2–
5.0 Gy), brain tumors (10–15 Gy) and liver tumors (13–17 Gy) imply that
the proton RBE for these tissues could vary significantly compared to the
commonly used generic value of 1.1. Our aim is to evaluate the impact of
this uncertainty on the proton dose in Gy(RBE) absorbed in normal and
tumor tissues. This evaluation was performed for standard and hypofractionated
regimens. RBE-weighted total dose (RWTD) distributions for 15 patients (five
prostate tumors, five brain tumors and five liver tumors) were calculated using
an in-house developed RBE model as a function of dose, dose-averaged linear
energy transfer (LETd) and (α/β)x. Variations of the dose–volume histograms
(DVHs) for the gross tumor volume (GTV) and the organs at risk due to
changes of (α/β)x and fractionation regimen were calculated and the RWTD
received by 10% and 90% of the organ volume reported. The goodness
of the plan, bearing the uncertainties, was then evaluated compared to the
delivered plan, which considers a constant RBE of 1.1. For standard fractionated
regimens, the prostate tumors, liver tumors and all critical structures in the brain
showed typically larger RBE values than 1.1. However, in hypofractionated
regimens lower values of RBE than 1.1 were observed in most cases. Based
on DVH analysis we found that the RBE variations were clinically significant
in particular for the prostate GTV and the critical structures in the brain.
Despite the uncertainties in the biological input parameters when estimating
RBE values, the results show that the use of a variable RBE with dose, LETd
and (α/β)x could help to further optimize the target dose in proton treatment
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planning. Most importantly, this study shows that the consideration of RBE
variations could influence the comparison of proton and photon treatments in
clinical trials, in particular in the case of the prostate.
(Some figures may appear in colour only in the online journal)
Introduction
The relative biological effectiveness (RBE) of protons in radiotherapy is known to depend
(among other factors) on the dose per fraction, the dose-averaged linear energy transfer (LETd)
distribution and the tissue α/β ratio obtained from cell survival curves after exposure to x-rays
((α/β)x). For proton dose distributions in a patient, LETd values can be up to six times larger
than in a therapeutic x-ray beam (110 MeV protons with LETd  12 keV μm−1 (Grassberger
et al 2011) compared to electrons with LETd  2 keV μm−1 produced from 10 MV photons
(Amols and Kliauga 1985)). Recent results show considerable variations of LETd values within
the irradiated volume in proton therapy (Grassberger et al 2011), which in combination with
findings on a dependence of RBE with tissue type (Gerweck and Kozin 1999) could imply
a departure of RBE from the average value of 1.1 for certain tissues or treatment scenarios.
Also, with the current tendency toward hypofractionated regimens in particle radiotherapy the
application of a generic RBE for all treatments might have to be revisited, especially since
there is very limited data from hypofractionated proton treatments.
This work aims at quantifying the theoretical departure of RBE from the accepted value
of 1.1 (Paganetti et al 2002) based on a previously published RBE model (Carabe-Fernandez
et al 2007) when the variability of the tissue (α/β)x is considered and the dose per fraction
is increased. Previous published work has been focused mainly on variations of RBE due to
changes of LETd (Grassberger et al 2011, Wilkens and Oelfke 2004, Tilly et al 2005, Frese
et al 2011), whereas this work analyzes in addition variations due to changes in (α/β)x and
dose per fraction. This analysis will be presented for the treatment of prostate, brain and liver
with proton therapy and compared with the dose–volume histograms (DVH) obtained from
biological dose distributions assuming a constant RBE.
Methods
We apply a model (Carabe-Fernandez et al 2007, 2010) that establishes the RBE dependence
with proton dose (dp), LETd and (α/β)x (equation (1)):
RBE[LETd, dp, (α/β)x] =
√
(α/β)2x+4(α/β)xRBEmax[LETd ,(α/β)x]dp+4(RBEmin[LETd ,(α/β)x])2d2p−(α/β)x
2dp ,
(1)
where RBEmax = αp/αx and RBEmin =
√
βp/βx with (αp, βp) representing the linear–quadratic
(LQ) parameters of cell survival curves for protons and (αx, βx) are the corresponding values
for x-rays. RBEmax and RBEmin are the asymptotic values of RBE at proton doses of 0 and
∞ Gy, respectively. In this work, the base values of RBEmax and RBEmin are derived from
values of α and β obtained from single dose survival curves of V79 cell cultures exposed to
x-rays and protons. However, the values of α and β for the cell lines of the tissues involved
in the treatment of the prostate, brain or liver, exposed to protons or x-rays are different.
The impact of those differences on the model predictions for RBEmax and RBEmin have been
incorporated using assumptions on how RBEmax and RBEmin change with tissue (α/β)x. There
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are considerable uncertainties when analyzing RBEmax and RBEmin as a function of α/β.
Based on the limited data available, this uncertainty seems to be larger for RBEmin. It has
been suggested that RBEmin could take values larger as well as smaller than unity (Das¸u 2007,
Carabe-Fernandez et al 2007).
The details explaining how RBE changes with LETd and (α/β)x are given in a previous
publication (Carabe et al 2012). In general, experimental data on proton RBE versus LETd
(Folkard et al 1996, Belli et al 1989, 1993, Perris et al 1986, Coutrakon et al 1997, Wouters
et al 1996, Schettino et al 2001) and proton RBE versus (α/β)x (Gerweck and Kozin 1999,
Paganetti et al 2000) indicate that RBE increases with increasing LETd (note that for protons
the eventual decrease with LETd happens at LETd values irrelevant for clinical considerations)
but decreases with increasing (α/β)x. The current data sets used to relate RBE with LETd and
(α/β)x are subject to uncertainties (Carabe et al 2012, Carabe 2013).
(i) The LETd distribution within a proton beam depends on the range (i.e. nominal energy
of the beam) and width of the spread out Bragg peak (SOBP). In particular, the larger the
range the lower the LETd values observed at any depth within the beam, and the larger
the width of the SOBP, the lower the LETd at the center of the SOBP. This complicates
the interpretation of the data used to establish the relationship between proton RBE and
(α/β)x (Gerweck and Kozin 1999) as it was measured at the center of the SOBP using
beams of different energies and with different SOBP widths.
(ii) If RBE is assumed to change with (α/β)x, then a new relationship between RBE and LETd
is required for every cell line or tissue type. The lack of data on RBE versus LETd for any
other cell line implies that we can only estimate how RBE relates to LETd for cell lines
with different (α/β)x. Equation (1) changes with LETd through RBEmax and RBEmin and
equations (2) and (3) show how the slope of the linear relationship between RBEmax and
RBEmin with LETd changes with (α/β)x. Equations (2) and (3) assume that RBEmax and
RBEmin change with (α/β)x and LET obeying a similar relationship, i.e. reciprocal to
(α/β)x and directly proportional to LET. However there is not sufficient data to confirm
the validity of such an assumption. An analysis of neutron data shows a possible different
relationship of RBEmin and (α/β)x (Jones et al 2011). According to a previous study the
uncertainty in (α/β)x translates into the uncertainty of RBEmax and RBEmin (Carabe et al
2012):
RBEmax[LETd, (α/β)x] = 0.843 + 0.154 2.686
(α/β)x
LETd, (2)
RBEmin[LETd, (α/β)x] = 1.09 + 0.006 2.686
(α/β)x
LETd . (3)
The RBE-weighted DVHs presented in the results are solely originated by the variation of the
slope of equations (2) and (3) due to the reported uncertainty range of the (α/β)x values of the
prostate, brain and liver.
The dependence of biological dose distributions on dose per fraction
In order to calculate the total doses relevant to the hypofractionated regimes, we have followed
the biological effective dose (BED) calculation guidelines recommended by The Royal College
of Radiologists (2008) and those recommendations by Dale et al (2002). In these guidelines
the strategy suggested for the BED calculation is to calculate the total dose required to
produce the same effect in the late-normal tissue and then to subsequently assess the likely
effect of the changed schedule on the tumor, rather than the other way around. This is
specifically recommended for the case of moving to a schedule with a smaller number of
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fractions, as in this case there is a real danger that the tolerance dose to the late-normal tissue
might be exceeded. Therefore, the resultant total hypofractionated doses were: TDBrain = 47.6
Gy, TDLiver = 51.5 Gy and TDProstate = 49.3 Gy for 10 fractions; and TDBrain = 31.4 Gy,
TDLiver = 34.4 Gy and TDProstate = 30 Gy for 3 fractions. For instance, in the case of prostate
(+ seminal vesicles) cases, the calculation of a hypofractionated treatment (3 or 10 fractions)
that would induce the same level of toxicity as the standard fractionation scheme (39 fractions)
would be performed as
78 (Gy)
(
1 + 2 (Gy)
3 (Gy)
)
= 10 d
(
1 + d
3 (Gy)
)
⇒ d = 4.93 (Gy),
where 78 Gy corresponds to the prescribed treatment dose, 2 Gy is the dose per fraction and
3 Gy corresponds to the assumed (α/β)x of the normal tissue involved in the treatment. The
fact that we are performing this calculation using a 1 within the brackets (i.e. . . . (1+ . . . ))
implies that this calculation is performed to obtain isoeffectiveness when comparing two
photon treatments using different number of fractions.
There were cases where the treatment target overlapped with a critical structure. In these
cases, the α/β used for the RBE calculation in the overlapping volume was the one from the
critical structure. It was assumed that these volumes would be constituted by both normal and
tumor cells, so a BED calculation that provides the total dose to deliver in a hypofractionated
treatment that produces the same effect in the late-normal tissue should preserve the effect on
the cells within the overlapping volume.
Calculation of the dose, LETd and RBE-weighted dose distributions
The proton dose and LETd distributions within the patients were calculated using Monte Carlo
simulations (Grassberger et al 2011, Paganetti et al 2008). The ‘variable’ RBE distributions
were calculated through equation (1) using the proton dose (normalized to the relevant dose
per fraction obtained from the BED calculation) and LETd distributions as well as assigned
values of (α/β)x to the different regions of interest (ROIs) involved in each plan. Figure 1
shows the dose distribution for one of the patients in each treatment site to provide an idea
of the location of the diseases being considered. The RBE-weighted dose per fraction was
multiplied by the number of fractions in order to obtain the RBE-weighted total dose (RWTD)
for the conventional and hypofractionated plans (RBE × Proton dose per fraction × number
of fractions). Table 1 summarizes the relevant radiobiological parameters as well as the
prescribed total doses currently used in this study for the treatment of the prostate gland,
craniopharyngioma and hepato-cellular carcinoma. These total doses are prescribed for the
treatment for either photon or proton treatments, but when protons are used the delivered dose
is divided by a factor of 1.1 to account for the clinical RBE.
Calculation of RWTD ranges and their uncertainty due to patient variability
No specific criterion was used to select the five patients in each site except for the similarity
in shape and location of the tumors in order to reduce the difference on the DVHs among each
patient group. The upper and lower limit of the RWTD ranges in table 2 are obtained as an
average of the RWTD for each patient in each site when the RBE is calculated according to
equation (1) using the respective lower and upper limit of (α/β)x indicated on the top of the
table for each tissue. Therefore, each of the numbers in table 2 is subject to a variance, which is
reported in table 3 (only for the standard fractionation when RBE = 1). For instance, the upper
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Figure 1. Representative distributions of physical dose, LET and RBE found in the brain, liver and
prostate treatment plans. The dose cutoff used to calculate the dose average LET distributions was
arbitrarily set at 0.1% of the target dose, which explains the noisiness of the distributions.
bound of the RWTD10% (when RBE = 1.1) for the left optical nerve, i.e. 41 Gy(RWTD)4 , is
derived as the average of the RWTD10% for each of the five brain patients (50.256, 30.678,
25.667, 47.059, 51.989 Gy(RWTD)). The resultant standard deviation (SD) in this case is
12.090 Gy(RWTD), as shown in table 3.
Results
Table 2 shows the numerical results of this analysis. The number in brackets indicates the
range of the RWTDs for each tissue at 10% and 90% of the organ volume. As expected these
ranges are always larger for the standard fractionation schemes with lower doses per fractions.
As each value in table 2 represents an average of the RWTDs obtained for each patient of
the five patients studied in each site, they have an uncertainty presented in table 3 in the form
of 1 SD. Only the SDs for the RWTD calculated with RBE = 1 in standard fractionations have
4 The standard unit for the RBE-weighted dose is Gy(RBE). In this study, dose is weighted with either a constant
(RBE = 1.1) or a variable (RBE = 1.1) RBE, so in order to distinguish how the RBE-weighted doses reported in this
study are obtained, we have used Gy(RBE) when RBE = 1.1 and Gy(RWTD) when RBE is considered to vary with
dose, LET or (α/β)x.
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Table 1. Target prescribed doses and dose constrains to the normal tissues used in this study for
prostate carcinomas, craniopharyngiomas and hepato-cellular carcinomas. The footnotes indicate
the literature source of the (α/β)x.
Prescribed dose and critical
structure dose constrains α/β (95% CI)
Prostate gland (standard number of fractions = 39)
GTV + seminal vesicles 78 Gy GTV: 1.5a (1.2b, 5.6c)
SEM V.: 3.0 (2.5, 3.5)
Rectum V75 < 10%, V70 < 70% 4.0d (2.5, 5.0)e
Bladder 4.0d (3.0, 7.0)e
Craniopharyngioma (standard number of fractions = 29)
GTV 72 Gy (x-rays + proton boost) 12f (10, 15)f
Brainstem No hot spot 2.1g (1.5, 3.9)g
Chiasm No hot spot 2.9i (1.5, 3.9)g
Optical nerve No hot spot (56–60 Gy) 1.6h (0.5, 10.3)h
Normal brain 2.9i (1.5, 3.9)g
Hepato-cellular carcinoma (standard number of fractions = 15)
GTV 60 Gy 15.0j (13.0, 17.0)j
Lung EUD < 20 Gy; or mean dose
<24 Gy (whichever lowest)/4 Gy
4.4k (1.5, 6.9)k
Healthy liver No hot spot 2.00j (1.5, 3.00)
a Brenner and Hall (1999).
b Ritter et al (2009).
c Das¸u (2007).
d Koukourakis et al (2007).
e Fowler (2005).
f Yuan et al (2008).
g Meeks et al (2000).
h Jiang et al (1994).
i Lawrence et al (2010).
j Tai et al (2008).
k Fowler (1989).
The CI of the (α/β)x are also included.
been included in table 3. In this table the ‘Upper’ and ‘Lower’ labels refer to SD of the upper
and lower values of the RWTD ranges presented in each cell of table 2 obtained for the lower
and upper values, respectively, of (α/β)x for each tissue. These SDs should be interpreted as
the uncertainty of the upper, central and lower lines of the biological DVHs in figures 2 and 3
(left panels) purely related to patient variability and not due to (α/β)x variability. According
to this table, the SDs of the RWTDs in the target volumes are small (1–6 Gy(RWTD)) in
the gross tumor volumes (GTVs) but larger SDs are observed in the large dose region (i.e.
10% volumes) in normal tissues, especially when the volume of the organ is small such as the
chiasm and optical nerve. There is a larger SD for lower (α/β)x.
Figures 2 and 3 show, on the left, the resultant biological DVH (RWTD-VH) for the
biological doses in the GTV and critical structures considering RBE = 1.1 compared to that
obtained when RBE is assumed dependent on dose, LETd and (α/β)x. To limit the number
of figures, only the RWTD-VHs for prostate and brain are shown as the effects found for
the liver cases were smaller. The shaded areas correspond to the RWTD obtained from the
RBE calculated from the top and bottom values of the (α/β)x confidence interval (CI), i.e. the
shaded areas solely correspond to the uncertainties in (α/β)x. Because it is difficult to separate
the influence from the LETd and the (α/β)x on the RBE, we have included the LETd- and RBE-
volume-histograms within each ROI for the nominal (central) values of (α/β)x in figures 2 and
3. For example, the LETd-volume-histograms for the prostate GTV and the seminal vesicles
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Table 2. Average RWTDs received by 10% and 90% of the GTV and organ-at-risk volumes in prostate, brain and liver proton therapy (five patients each). The number in brackets in
each cell represents the RWTD range when RBE = 1.1. ‘n’ represents the number of fractions. The units of the RWTD obtained from variable RBE (RBE = 1.1) is Gy(RWTD), while
that obtained from a constant RBE (RBE = 1.1) is measured in Gy(RBE).
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3
RWTD10 RBE 1.1 
36-49 
(13) 
31-32 
(1) 
29.6-29.8 
(0.2) 
30.9-31.3 
(0.4) 
14.6-14.8 
(0.2) 
11.6-11.8 
(0.2) 
31.7-32.6 
(0.9) 
30.7-33.5 
(2.8) 
29.8-32.8 
(3) 
23.4-26.7 
(3.3) 
22.0-25.6 
(3.6) 
RBE=1.1 35.5 33.9 32.4 32.4 15.8 12.3 33.7 33.6 32.5 25.58 24.5 
RWTD90 RBE 1.1 
35-47 
(12) 
8-9 
(1) 0.1 
29.2-29.6 
(0.4) 0.01 0
29.9-32 
(2.1) 
29.8-32.6 
(2.8) 
0.02-0.03 
(0.01) 
0.08-0.13 
(0.05) 
0.08-013 
(0.05) 
RBE=1.1 34.5 9.1 0.12 30.6 0.01 0 32.3 32.6 0.03 0.08 0.08 
n
=
1
0
RWTD10 RBE 1.1 
57-80 
(23) 
49-50 
(1) 
46-47 
(1) 
48.6-49.4 
(0.8) 
23.1-23.5 
(0.4) 
18.6-19.8 
(1.2) 
52.3-58.3 
(6) 
50.2-58.3 
(8.1) 
48.9-57.4 
(8.5) 
39-48 
(9.0) 
36-46 
(10) 
RBE=1.1 55.5 52.9 50.5 50.5 24.6 19.2 55.1 54.8 53.0 41.8 39.9 
RWTD90 RBE 1.1 
56-77 
(21) 
13-14 
(1) 0.20 
45.8-46.7 
(0.9) 0.01 0.01 
49-53.2 
(4.2) 
48.8-56.6 
(7.8) 
0.04-0.07 
(0.03) 
0.15-0.23 
(0.08) 
0.16-0.20 
(0.4) 
RBE=1.1 53.8 14.1 0.20 47.6 0.01 0.01 52.8 53.2 0.05 0.15 0.17 
S
t
a
n
d
a
r
d
F
r
a
c
t
i
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n
a
t
i
o
n RWTD10 
RBE 1.1 94-139 (45) 
79-82 
(3) 
74.9-77.2 
(2.3) 
65-66 
(1) 
31.1-31.6 
(0.5) 
25-26.7 
(1.7) 
56-71 
(15) 
53-71 
(18) 
52-72 
(20) 
41-62 
(21) 
39-59 
(20) 
RBE=1.1 88.26 84.2 80.4 67.5 32.9 25.6 58.0 57.7 55.8 43.9 42
RWTD90 
RBE 1.1 91-133 (42) 
22-24 
(2) 
0.31-0.34 
(0.03) 
61-62 
(1) 0.01 0.01 
52-57 
(5) 
52-69 
(17) 0.1 
0.1-0.2 
(0.1) 
0.1-0.2 
(0.1) 
RBE=1.1 85.7 20.7 0.32 63.7 0.01 0.01 55.5 55.9 0.07 0.2 0.16 
Prostate  Liver  Brain  
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Table 3. SD of the upper and lower bound of the RWTD ranges presented in table 2 for the standard
number of fractionation.
Liver Prostate Brain
Healthy Ant. Lt opt. Rt opt.
GTV Lung liver GTV rectum Bladder GTV Chiasm Brainstem nerv. nerv.
Upper 10% 4.982 7.534 23.065 2.071 9.439 3.026 4.736 6.302 3.749 12.090 13.491
90% 1.695 0.018 0.007 2.576 5.396 0.349 2.606 8.147 0.119 0.182 0.230
Center 10% 6.631 10.073 22.737 4.352 5.308 2.947 5.566 7.932 3.212 14.041 11.346
90% 1.085 0.019 0.007 4.504 3.772 0.267 3.999 7.620 0.121 0.243 0.235
Lower 10% 2.884 7.535 18.054 2.933 3.977 2.390 1.052 7.863 3.974 11.107 13.990
90% 2.345 0.019 0.000 4.501 2.798 0.090 1.998 6.924 0.082 0.296 0.295
are very similar, but because the physical dose received by the seminal vesicles is lower than
the GTV one might expect a larger RBE in the seminal vesicles. The RBE values in the prostate
are higher than for the seminal vesicles because tissues with lower (α/β)x, such as the prostate,
the optic nerves and the brainstem, cause elevated RBE values.
The step in the RWTD-VH curve of the brain GTV at the 80% volume level in figure 3 is
due to an overlap of the brainstem contour with the GTV contour. Because of the low (α/β)x
of the brainstem (1.5 Gy) compared to the GTV (10 Gy) we see an increase of the RWTD of
the GTV. The higher (α/β)x boundary of the RWTD-VH for the GTV is not equally affected
because the high (α/β)x cause a smaller variation in the already low RBE value.
According to table 2, the following features can be observed.
(1) The RWTD ranges become wider (larger RBE uncertainty) for low (α/β)x and larger
number of fractions (i.e. lower dose per fraction). This is particularly clear when comparing
the three GTV columns in table 2, which shows the following.
(a) For prostate (1.2 Gy < α/β < 5 Gy) the average range of RWTD received by 90%(
RWTD90%Avg
)
of the GTV is 25 Gy(RWTD) (for the three fractionation schemes
in table 2: (42 + 21 + 12)/3 Gy(RWTD)) with a maximum of 42 Gy(RWTD) for
standard number of fractions and a minimum of 12 Gy(RWTD) for hypofractionated
treatments. The 10% of the GTV receives an average range of RWTD
(
RWTD10%Avg
)
of 27 (45–13) Gy(RWTD).
(b) For brain (10 Gy < α/β < 15 Gy):
RWTD10%Avg = 7.3 (15–0.9) Gy(RWTD),
RWTD90%Avg = 3.8 (5–2.1) Gy(RWTD).
(c) For liver (13 Gy < α/β < 17 Gy):
RWTD10%Avg = 0.7 (1–0.4) Gy(RWTD),
RWTD90%Avg = 0.8 (1–0.4) Gy(RWTD).
(2) The RWTD uncertainty in the case of the rectum, bladder, lung and normal liver was
found lower even for large uncertainties in the (α/β)x.
(a) Rectum (2.5 Gy < α/β < 5 Gy):
RWTD10%Avg = 1.7 (3–1) Gy(RWTD),
RWTD90%Avg = 1.3 (2–1) Gy(RWTD).
(b) Bladder (3 Gy < α/β < 7 Gy):
RWTD10%Avg = 1.2 (2.3–0.2) Gy(RWTD),
RWTD90%Avg = 0.01 (0.03–0) Gy(RWTD).
(c) Lung (1.6 Gy < α/β < 6.9 Gy):
RWTD10%Avg = 0.4 (0.5–0.2) Gy(RWTD),
Clinical consequences of RBE variations in proton radiotherapy of the prostate, brain and liver 2111
Figure 2. Results obtained as an average of five patients treated with protons for
craniopharyngioma. ‘n’ represents the number of fractions. Left: DVHs of the RWTDs for the
prostate GTV and the organs at risk. Each line is obtained from either the RWTD weighted by an
RBE of 1.1 or a variable RBE that depends on dose, LETd and (α/β)x. The gray bands correspond
to the uncertainty of the RWTD due to the uncertainty of the tissues (α/β)x. Right: the RBE- and
LETd-volume-histograms representing the distribution of RBE and LETd calculated within each
organ. The solid black line corresponds to the LETd, while the dashed lines correspond to the RBE
for different doses per fraction. The vertical dashed line corresponds to a constant RBE of 1.1.
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Figure 3. Results obtained as an average of five patients treated with protons for prostate cancer.
‘n’ represents the number of fractions. Left: DVHs of the RWTDs for the brain GTV and the
organs at risk. Each line is obtained from either the RWTD weighted by an RBE of 1.1 or a variable
RBE that depends on dose, LETd and (α/β)x. The gray bands correspond to the uncertainty of the
RWTD due to the uncertainty of the tissues (α/β)x. Right: the RBE- and LETd-volume-histograms
representing the distribution of RBE and LETd calculated within each organ. The solid black line
corresponds to the LETd, while the dashed lines correspond to the RBE for different doses per
fraction. The vertical dashed line corresponds to a constant RBE of 1.1.
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RWTD90%Avg = 0.01 Gy(RWTD).
(d) Healthy liver (1.5 Gy < α/β < 3 Gy):
RWTD10%Avg = 1.0 (1.7–0.2) Gy(RWTD),
RWTD90%Avg = 0 Gy(RWTD).
(3) Normal tissues with small (α/β)x exposed to larger values of LET do present large RWTD
uncertainties, such as in the case of the following.
(a) Chiasm (1.5 Gy < α/β < 3.9 Gy):
RWTD10%Avg = 9.6 (18–2.8) Gy(RWTD),
RWTD90%Avg = 9.2 (17–2.8) Gy(RWTD).
(b) Brainstem (1.5 Gy < α/β < 3.9 Gy):
RWTD10%Avg = 10.5 (20–3) Gy(RWTD),
RWTD90%Avg = 0.01 (0.01–0.03) Gy(RWTD).
(c) Optical nerves (averaged for both nerves) (0.5 Gy < α/β < 10.3 Gy):
RWTD10%Avg = 11.2 (21–0.01) Gy(RWTD),
RWTD90%Avg = 0.13 (0.4–0.05) Gy(RWTD).
(4) The RWTD uncertainty for large doses (hypofractionated schemes) is smaller than
for small doses (standard fractionation). This is corroborated by looking at figures 2
and 3 where the shaded areas of RWTD become narrower when going from standard
fractionation to the hypofractionated schemes. As the total dose required in the
hypofractionated regimes is lower, smaller uncertainties in the RWTD are expected.
(5) It seems that for 50% of the hypofractionated treatments in table 2 (22 cells out of 44 in
the n = 10 and n = 3 rows), the RWTD for a constant RBE is larger than the RWTD
range for a variable RBE, whereas for the remaining 50% the RWTD for a constant RBE
is within or below the RWTD range for a variable RBE. This could potentially imply that,
when using hypofractionated schedules, one might have to decrease the dose required to
maintain tumor control while reducing the entrance dose as well as the dose to critical
organs.
Discussion
Biological optimization of proton treatments requires the consideration of the full range of
RBE values across the SOBP as a function of LETd, dose and (α/β)x. However there is not
sufficient data to calculate these values for all tissues as (α/β)x is not precisely known for
all tissues. The RBE value of 1.1 has proven to be a good average representation across
the SOBP at any dose and for all tissues (Paganetti et al 2002). Nevertheless, if we want
to increase the accuracy of our treatment to levels below 5–10% of uncertainty, we need to
consider biological effect variations that are above this level. Table 2 as well as figures 2
and 3 show in what circumstances (i.e. combination of (α/β)x and/or doses per fraction)
these levels of uncertainty are exceeded. According to table 2, the uncertainty levels of the
RWTD (expressed as a percentage of the clinical biological dose: 1.1 × Prescribed dose)
due to the variability of the tissue (α/β)x are above 10% uncertainty, with a maximum of
52.3% in the case of the prostate GTV (using the RWTD10 range for standard fractionation:
Uncertainty(%) = RWTD range1.1×Prescibed dose × 100% = 45 (Gy(RWTD))1.1×78.3 (Gy) × 100%), 2.6% in the case of
healthy liver (from the RWTD10 range in standard fractionation: 1.7 (Gy(RWTD))1.1×60.2 (Gy) × 100%).
These percentages decrease for hypofractionated regimes.
The ranges of RWTD on the top of every cell in table 2 are due to the variability of (α/β)x,
and the size of these ranges can be evaluated when using different fractionation schemes (or
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different dose levels). However, the dependence of RWTD with Let also has an important
impact on how RWTD varies with (α/β)x and dose per fraction, specially from the point of
view that RBE increases with increasing LET but decreases with increasing (α/β)x or dose.
Thus, organs with large values of (α/β)x receiving large values of LET may not present a large
RWTD range. This effect can be seen in the case of the bladder, which according to figure 2
receives the highest values of LET in the case of prostate treatments, but this organ also has
the largest values of (α/β)x of this site, so that could potentially explain why the RWTD
uncertainty for the bladder is small even for a large uncertainty in the (α/β)x as explained in
feature (2) of the results. The same reasoning could apply to the anterior rectum, which also
receives higher LET than the GTV or seminal vesicles but the RWTD range is low even for
large ranges of (α/β)x. As the (α/β)x values related to the rectum are lower than those for the
bladder larger RWTD ranges are observed. As the rectum and the bladder are symmetrically
placed on the sides of the prostate, it could be assumed that they both receive a similar dose, so
the above discussion is independent of dose differences received by both organs. Also, within
the discussion of competing effects between LET and (α/β)x on RWTD, it is interesting to
note that, in the case of the prostate GTV where the LET decreases to values just above
2 keV μm−1 but the lower bound of the (α/β)x range goes as low as 1.2 Gy, a larger decrease
of LET would have been required to compensate for such low values of (α/β)x in order to
have small variations of RWTD. This feature clearly shows how important is the impact on
RBE due to variations of (α/β)x versus variations of LET.
According to figure 1, the critical structures in the brain are subjected to a rapid decrease
of dose (dose falloff), and increased LET and very large ranges of (α/β)x going from 0.5
to 10 Gy. According to what has been discussed above, and considering that in this case all
three factors (dose, LET and (α/β)x) work in the same direction to increase RBE, it is not
surprising to find the largest RWTD ranges overall in this site. This shows how, in the case
of brain treatments, radiobiological considerations in proton treatment planning are of special
importance compared to any other treatment site. In the case of the liver, the larger RWTD
ranges are observed in the healthy liver where again the low (α/β)x, the increased LET values
(as the beams stop in the healthy liver in most of the cases) and the dose falloff imply larger
values of RBE. The ranges are however not very large in the healthy liver due to the small
range of (α/β)x.
The correctness of these conclusions and the results of the present analysis is based on the
validity of equations (2) and (3), but there is not sufficient data to either confirm or refute their
validity. The large uncertainties discovered in the case of the prostate and the brain, imply
that more data are required before considering correcting for RBE effects. For this reason, a
better approach in this case would be to use a beam arrangement that allows placing the high
LET components of the beam away from the critical structures (Grassberger et al 2011). This
was not feasible for the planning and delivery scenario considered in this study because we
considered passive scattering treatments. Note also that an unaccounted increase of RBE in
the distal falloff can cause the extension of the distal edge of the biological dose by a few
millimeters (Robertson et al 1975, Carabe et al 2012).
As part of the discussion on the uncertainty of the RBE values derived in this work, we
need to refer to the questionable validity of the LQ model (and therefore of equation (1)) for
the doses per fraction of the hypofractionated regimens used here. The largest dose used in
the calculations of the RBE was 11.5 Gy in the case of the liver (34.4 Gy delivered in three
fractions). However, there are studies (Brenner 2008) suggesting the validity of the LQ at doses
as high as 18 Gy of photons but no equivalent value has been suggested for protons (although
it is assumed that it will be lower due to the high-LET components in a proton beam). It is
therefore difficult to quantify the uncertainty induced by this limitation in the LQ model.
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Figure 4. Difference in the interpretation of how the relationship between RBE and LET should
change with the LQ model parameters by Frese et al (2011) and Carabe-Fernandez et al (2007).
The impact of variable RBE values in proton therapy has been modeled before (Tilly et al
2005, Frese et al 2011). Tilly et al found that the ratio of αproton/αx (equals RBEmax in this
work) linearly increases with LETd, and that the slope of this linear relationship increases
with decreasing (α/β)x. However, in their study, the linear relationship between αproton/αx and
LETd was established based on only two values of (α/β)x (2 and 10 Gy) and a sensitivity
analysis of the change of slope was performed by providing a maximum and minimum slope
corresponding to the estimated error associated with the experimental values of (α/β)x. Thus,
the analysis was performed for tissues with (α/β)x equal or around 2 and 10 Gy. In contrast,
our analysis handles the change of slope with (α/β)x as part of the model input parameters
RBEmax and RBEmin. Our approach will allow us to incorporate additional experimental data for
(α/β)x values, if they become available. Furthermore, the inclusion of RBEmin in equation (1)
makes our model suitable to predict RBE effects in hypofractionated regimens.
The model by Frese et al (2011) is similar to equation (1) with the difference that it
assumes a constant βx as a function of LETd. The model does consider a change of the slope
of the relationship between αprotons and LETd via the parameter λ:αprotons = αo + λ · LETd,
where αo corresponds to a normalization parameter such that in the entrance of the proton
beam the RBE equals 1.0. The parameter λ is independent of the biological tissue and the tissue
dependence is solely described by αo, which depends on αx. The difference to our approach
is illustrated in figure 4. A relationship similar to the one proposed in our work has been
proposed by others (Hawkins 1994, 2003). In contrast to the model by Frese et al one might
assume that in the case of a cell or tissue with a low αx, low LETd values will not necessarily
yield large values of RBE according to our model. Furthermore, the approach by Frese et al
relies on the knowledge of αx instead of (α/β)x alone.
As we have shown, considering variations in the biological effect of proton beams might
offer the potential to further optimize proton therapy treatments. Furthermore, biological
considerations beyond simply using an RBE of 1.1 might be warranted when comparing
photon and proton treatments in clinical trials, in particular for tissues with low (α/β)x ratios,
such as prostate.
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